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A New Triggering Receptor Expressed on Myeloid Cells
(Trem) Family Member, Trem-Like 4, Binds to Dead Cells
and Is a DNAX Activation Protein 12-Linked Marker for
Subsets of Mouse Macrophages and Dendritic Cells1
Hiroaki Hemmi,2*† Juliana Idoyaga,† Koji Suda,† Nao Suda,† Kathleen Kennedy,‡
Masaki Noda,§ Alan Aderem,‡ and Ralph M. Steinman2†
Dendritic cells (DCs) are professional APCs that can control immune responses against self and altered self, typically foreign,
determinants. DCs can be divided into several subsets, including CD8 and CD8 DCs. These subsets possess specific functions.
For example, mouse splenic CD8, but not CD8 DCs selectively take up dying cells and cross-present cell-associated Ags to
naive T cells. In this study, we identified genes that were more expressed in CD8 than CD8 DCs by microarray analysis. Only
one of these genes, when the extracellular domains were linked to human IgG Fc domain, could bind to late apoptotic or necrotic
cells. This gene was a new member of the triggering receptor expressed on myeloid cells (Trem) family, Trem-like 4 (Treml4).
Treml4 mRNA and protein, the latter detected with a new mAb, were predominantly expressed in spleen. Treml4, like other Trem
family members, could associate with the adaptor molecule DNAX activation protein 12 kDa, but neither DNAX activation protein
10 kDa nor FcR. Consistent with the microarray data, we confirmed that Treml4 protein was more expressed on CD8 than CD8
DCs, and we also found that Treml4 was expressed at high levels on splenic macrophages in spleen, particularly red pulp and marginal
metallophilic macrophages. In addition, Treml4 expression on DCs was not changed after maturation induced by TLR ligands. Thus,
Treml4 is a new Trem family molecule that is abundantly expressed on CD8 DCs and subsets of splenic resident macrophages, and
can recognize dead cells by different types of phagocytes in spleen. The Journal of Immunology, 2009, 182: 1278–1286.
D endritic cells (DCs)
3 consist of several subsets that are
classified according to their expression of select cell sur-
face molecules and distinct functions. In mouse spleen,
for example, there are CD8 DEC-205 CD11c and CD8
DCIR2 CD11c classical DCs, and B220 CD11cdull plasma-
cytoid DCs. CD8 spleen DCs are the predominant producers of
IL-12 upon stimulation with Toxoplasma gondii (1, 2), and selec-
tively engulf different types of dying cells, including allogeneic cells
killed by NK cells, irradiated tumor cells, and virus-infected cells (3,
4). Furthermore, CD8 DCs are superior cells for the cross-presen-
tation of Ags on MHC class I molecules (5–7). Molecular mecha-
nisms for these distinct functions are starting to be identified, e.g.,
CD8 DCs express higher levels of mRNA transcripts and proteins
involved in the MHC class I processing pathway (7).
Apoptotic cells are generated continually in mammals and other
species, and cell death is increased further during embryo develop-
ment, tissue remodeling, and inflammation. Potentially harmful cells
that are eliminated by apoptosis include self-reactive T and B cells,
tumor cells, and cells infected with viruses and some bacteria. En-
gulfment of apoptotic cells in some instances suppresses production
of inflammatory cytokines from activated macrophages (8). When
dying cells are engulfed by DCs in the steady state in the absence of
infection or immunological adjuvants, Ag-specific tolerance to Ags in
the dying cells can be induced (3). In contrast, if mice are given dying
cells with adjuvants, Ag-specific T cell responses develop (3, 9).
Analyses of genetically modified mice have shown that increased ac-
cumulation of apoptotic cells induces the development of autoim-
mune diseases (10–12). Thus, accumulating evidence indicates that
the uptake of apoptotic cells is not only a clearance mechanism, but is
also capable of suppressing inflammation and modulating immune
responses from Ag-specific tolerance to resistance (13).
In vitro studies indicate that many receptors can be involved
in the uptake of dying cells by macrophages, including scav-
enger receptors, the phosphatidylserine receptor, integrins,
CD14, C1q, C1qR, and CD36 (14 –21). Recently, the T cell Ig
and mucin domain-containing molecules, Tim-1 and Tim-4,
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were shown to recognize phosphatidylserine and mediate apo-
ptotic cell uptake (22–24). Recent in vivo studies have shown
that the Mer tyrosine kinases (Mertk) and milk fat globule epi-
dermal growth factor 8 contribute to the engulfment of apopto-
tic cells by macrophages (11, 12). Sen et al. (25) also reported
that Mertk mediates suppression of NF-B activation in DCs
that take up dying cells. Mertk also suppresses the maturation
and cytokine production by DCs taking up apoptotic cells, and
mediates induction of immunological tolerance (25, 26). CD36
and DEC-205 (CD205) are two receptors that are expressed
more abundantly on CD8 than CD8 DC subset in mouse
spleen, but each of these molecules is dispensable for uptake of
dying cells by CD8 DC in vivo (3, 27, 28).
To identify gene(s) involved in dying cell uptake and signaling
by DCs, we compared gene expression by DNA microarrays from
mouse splenic CD8 and CD8 DCs, where the former are
specialized to clear apoptotic cells. Several transmembrane genes
were more expressed by CD8 DCs, but the soluble form of only
one of them, the triggering receptor expressed on myeloid cells
(Trem)-like 4 (Treml4), exhibited binding to dead cells. We will
describe these findings as well as the capacity of Treml4 to asso-
ciate with an adaptor molecule DNAX activation protein 12 kDa
(DAP12) and to serve as a marker for select groups of both DCs
and macrophages. Surprisingly, macrophages in spleen, but not
several other organs, expressed Treml4. Thus, we have identified
a new type of molecule with the potential to recognize dead cells
and signal different types of splenic phagocytes.
Materials and Methods
Mice
C57BL/6 and BALB/c mice were purchased from Charles River Labora-
tories, Taconic Farms, or CLEA Japan. All mice were maintained under
specific pathogen-free conditions and used at 6–12 wk of age under insti-
tutional guidelines of the Rockefeller University and Tokyo Medical and
Dental University.
Cell lines
B16.Flt3L cells, which produce mouse Fms-like tyrosine kinase 3 ligand
(Flt3L), were established via retroviral gene transfer to B16 melanoma cell
line by Dranoff et al. (29) and provided by L. Santambrogio (Albert Ein-
stein College of Medicine, New York, NY). A hybridoma clone, 2.4G2,
was from American Type Culture Collection. Human embryonic kidney
(HEK) 293A and 293T cells were cultured in DMEM supplemented with
10% FBS and 10 mM HEPES.
Abs and reagents
Purified anti-CD16/32 (clone 2.4G2) or FITC-, PE-, allophycocyanin-, or
biotin-conjugated anti-CD3 (145-2C11), anti-B220 (RA3-6B2), anti-
CD11c (HL3), and anti-CD8 (53-6.7) were from BD Biosciences. Anti-
CD11c beads (N418) and anti-PE beads were from Miltenyi Biotec. FITC-
conjugated anti-human IgG (H  L) was from Jackson ImmunoResearch
Laboratories. Purified anti-Treml4 mAb was biotinylated with EZ-link
NHS-biotin reagent (Pierce), according to manufacturer’s instructions. LPS
(O55:B5) was from Sigma-Aldrich. Polyinosine-polycytidylic acid (poly(I:
C)) was from GE Healthcare or InvivoGen. Phosphorothioate-stabilized
CpG deoxyoligonucleotides (CpG DNA, 5-TCCATGACGTTCCTGAT
GCT-3) were purchased from Genelink or Qiagen.
FIGURE 1. Microarray analysis of two Flt3L-expanded DC subsets from mouse spleen. A, In vivo expanded mouse splenic DCs (Materials and
Methods) were sorted from CD3 B220 CD11c fractions (left panel). The purities of CD8 and CD8 DCs were 94 and 91%, respectively (middle
and right panels). B, DNA microarray analysis was performed using RNAs from CD8 and CD8 DCs. Names of representative genes are indicated.
Cadm1, cell adhesion molecule1; Itgae, integrin E; Mpzl2, myelin protein zero-like 2; Fndc5, fibronectin type III domain containing 5. C, A semiquan-
titative RT-RCR was conducted in two DC subsets. The numbers in parentheses indicate the number of PCR cycles.
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Cell sorting
B16.Flt3L cells were cultured with DMEM containing 10% FBS, and 5 
106 cells were injected into the backs of mice. After 10–12 days, when the
secreted Flt3L had greatly expanded the numbers of all major DC subsets
(30), the spleens were collected and cut into small fragments. Single-cell
suspensions were prepared by treating with collagenase D (Roche Applied
Science). After adding anti-CD16/32 mAb or 2.4G2 hybridoma superna-
tant to block nonspecific binding of Abs, the cells were stained with FITC-
conjugated anti-CD3 and anti-B220, PE-conjugated anti-CD11c, and al-
lophycocyanin-conjugated anti-CD8. After washing, CD11c DCs were
enriched by positive selection using anti-PE magnetic beads and MACS
columns (Miltenyi Biotec). CD8CD11c or CD8CD11c cells were
then sorted from the electronically CD3- and B220-negative fractions by
FACSVantage (BD Biosciences). The purity of each fraction was more
than 98%.
Microarray analysis
Total RNA was isolated from the sorted cells by TRIzol (Invitrogen) and
subjected to microarray analysis using the mouse genome 430 2.0 array
(Affymetrix). The data were analyzed by GeneSpring software (Agilent).
Microarray data were deposited in National Center for Biotechnology In-
formation’s Gene Expression Omunibus with the accession number
GSE13250.
RT-PCR and real-time PCR
Total RNA was isolated from sorted cells or tissues by TRIzol and used to
synthesize cDNA with Superscript III (Invitrogen). Semiquantitative PCR
was performed using primer pairs indicated in Supplemental Table I.4
Real-time quantitative PCR was performed with the iCycler iQ real-time
PCR detection system (Bio-Rad).
Cloning of Treml4
Mouse Treml4 cDNA was amplified by PCR, cloned into pCR2.1 vector
(Invitrogen), and sequenced. The sequence of cloned Treml4 open reading
frame was identical with a clone registered on GenBank (accession number
BC117091). PCR primers were sense, 5-GACTGGTATGGCCTGGAG
GTACTC-3 and antisense, 5-GCCTGTTCTGCCTTAGTACCAGTT-3.
Production of soluble proteins
To produce soluble forms of several transmembrane proteins, cDNA frag-
ments encoding the extracellular region of each gene were amplified by
PCR and cloned into an expression vector containing the exons for hinge,
CH2, and CH3 region of human IgG1 (31). The fusion proteins were pro-
duced by transient transfection of HEK293T cells using calcium phosphate.
Cells were cultured in serum-free DMEM supplemented with 1% Nutri-
doma SP (Roche Applied Science) for 4–5 days. The fusion proteins were
purified from culture supernatants using protein G-Sepharose beads (GE
Healthcare Bioscience) after ammonium sulfate precipitation.
Preparation of dying or dead cells
Splenocytes or thymocytes were prepared from C57BL/6 mice, irradiated
with -ray (1500 rad), and cultured for 5 h to induce apoptosis. To prepare
necrotic cells, splenocytes or thymocytes were incubated at 56°C for 30
min or 100°C for 10 min. These dying or necrotic cells were incubated with
propidium iodide (PI; BD Biosciences) or 7-aminoactinomycin D (BD Bio-
sciences) together with annexin V (BD Biosciences), according to manu-
facturer’s instructions.
Flow cytometry
Dying or dead cells were incubated with anti-CD16/32 Ab to block non-
specific Fc binding, and then incubated with soluble fusion proteins. After
washing, binding to dying or necrotic cells was detected by incubating with
FITC-conjugated anti-human IgG Ab (Jackson ImmunoResearch Labora-
tories) and analyzed on a FACSCalibur (BD Biosciences).
To check for expression of Treml4 on splenic CD11c DCs, whole
splenocytes, or lymph node cells, each population was first incubated with
biotinylated anti-Treml4, the indicated fluorescent Abs, and exposed allo-
phycocyanin- or PE-conjugated streptavidin (BD Biosciences), and ana-
lyzed on a FACSCalibur or Guava EazyCyte Mini (Guava Technologies).
Data were analyzed by FlowJo software (Tree Star).
Coimmunoprecipitation assay and Western blotting
To construct the expression vectors for FLAG-tagged Treml4 and myc-
tagged DNAX activation protein 10 kDa (DAP10), DAP12, and FcR,
each cDNA was amplified by PCR, sequenced, and inserted into pcDNA3.1
vector (Invitrogen). HEK293A cells were transiently transfected with the in-
dicated combination of expression vectors using Lipofectamin2000 (Invitro-
gen). Whole-cell lysates were prepared 36 h after transfection with lysis buffer
containing 50 mM Tris-HCl, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA,
1% Triton X-100, and 10% glycerol, and precipitated with anti-FLAG M2 Ab
(Sigma-Aldrich) and protein G-Sepharose beads (GE Healthcare Bioscience).
The immunoprecipitates were separated on a 5–20% polyacrylamide gradient
gel (Bio-Rad) and transferred onto a polyvinylidene difluoride membrane. The
membrane was incubated with HRP-conjugated anti-myc mAb (9E10; Roche).
Peroxidase activity was detected with the ECL Plus System (GE Healthcare
Bioscience).
For Western blotting of tissue lysates, spleen, liver, lung, bone marrow,
peritoneal lavage, and peripheral lymph nodes (popliteal, cervical, ingui-
nal, axillary, and brachial) were collected. Organs were meshed with two
frozen slides. The cells were collected and solubilized in radioimmunopre-
cipitation assay buffer (25 mM Tris (pH 7.6), 150 mM NaCl, 1% Nonidet
P-40, 1% sodium deoxycholate, 0.1% SDS, and 5% protease inhibitor mix-
ture; Sigma-Aldrich) for 15 min at 4°C. Cell lysates were sonicated to
homogenize and then quantified by DC protein assay (Bio-Rad). Equal
amounts of protein were separated by 4–12% polyacrylamide NuPage bis-Tris
gels (Invitrogen) and transferred to polyvinylidene difluoride membranes (In-
vitrogen). Membranes were incubated with the primary Ab, washed, and in-
cubated with peroxidase-conjugated species-specific Ab (Supplemental Table
IIa).4 After washing, membranes were developed with ECL Plus System. To
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FIGURE 2. Binding of chimeric fusion proteins to apoptotic or necrotic
cells. Splenocytes (A) or thymocytes (B) were exposed to -irradiation to
induce apoptosis, and then stained with the indicated chimeric fusion pro-
teins. The binding of fusion proteins was evaluated by FACS. Apoptosis
was monitored by staining with PI and annexin V. C, Thymocytes were
incubated at 100°C for 10 min to induce necrosis, stained with fusion
proteins, and then analyzed by FACS. Representative data from at least two
independent experiments are shown.
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Blot Stripping Buffer (Thermo Scientific), washed, and immunoblotted using
an anti-actin mAb (Sigma-Aldrich). Developed films were analyzed by den-
sitometry using computerized image analysis software (MCID-M5; Imaging
Research), and the data were normalized as follows: protein band (density 
area)/actin (density  area). Student’s t test was applied to reveal significant
differences in protein expression between BALB/c and C57BL/6 mice.
Production of anti-Treml4 mAb
A chimeric protein consisting of Treml4 extracellular portion and human
IgG1 Fc portion was used to immunize Wistar rats four times. One month
after fourth immunization, purified FLAG-tagged extracellular domain of
Treml4 was injected for a final boost. Three days later, splenocytes were
fused with myeloma cell line P3  63.Ag14. Production of mAb against
Treml4 was screened by ELISA using Treml4-FLAG protein. Two hybrid-
oma clones, named 16E5 and 32D11, were established, but they produced
the identical Ab (IgG1,  L chain).
Immunofluorescence staining
Spleens were harvested and frozen in Tissue-Tek OCT compounds (Sakura
Finetek). Frozen tissue was sectioned at 10 m in thickness on a microtome
(Microm Laborgeräte), fixed for 15 min with cold acetone, rehydrated in PBS,
and blocked with avidin/biotin-blocking reagents (Zymed Laboratories), ac-
cording to the manufacturer’s instructions. Sections were first blocked with 5%
mouse serum in FACS buffer (2% FCS in PBS) for 60 min at room temper-
ature, and then stained in humidified chamber overnight at 4°C with primary
Abs (Supplementary Table IIb). After washing in FACS buffer, sections were
stained with anti-FITC Alexa 488 and streptavidin Alexa 555 (Molecular
Probes, Invitrogen) diluted in FACS buffer/2% mouse serum. Specific intra-
cellular adhesion molecule-grabbing nonintegrin receptor 1 (SIGN-R1) stain-
ing was performed using anti-hamster FITC (Jackson ImmunoResearch Lab-
oratories), followed by anti-FITC Alexa 488. Sections were mounted in Aqua-
Poly Mount (Polysciences) and were stored at 4°C until microscopic
examination. The images were acquired with a Zeiss LSM 510 system (Carl
Zeiss MicroImaging) at the Rockefeller University Bio-Imaging Resource
Center.
Results
Microarray analysis of mouse splenic DC subsets
To identify gene(s) involved in the uptake and signaling of dying
cells by DCs, we conducted a DNA microarray analysis using
sorted mouse splenic CD8 and CD8 DCs. Because the num-
ber of splenic DCs is quite low, we initiated s.c. tumors with
B16.Flt3L cells that had been retrovirally transduced to express
mouse Flt3L (29) to expand DCs. These in vivo expanded DCs
showed similar phenotypes to that observed in nontumor-carrying
animals, and functioned similarly in terms of cytokine production
in response to bacterial products, stimulation of T cells in the
MLR, and uptake of dying cells by CD8 DCs (data not shown).
Ten to 12 days after injection of Flt3L tumor cells, splenic
CD11c DCs were enriched by MACS and further purified by
FACS cell sorter into CD8 and CD8 subsets. Their purities
were more than 90% (Fig. 1A). On microarray, several genes for
predicted transmembrane proteins were differentially expressed by
FIGURE 3. Association of Treml4
with DAP12. A, Amino acid sequence
alignment of human and mouse
Treml4. Human (GenBank accession
number NM198153) and mouse
Treml4 share an overall amino acid
identity of 39.9%. The predicted sig-
nal peptide (mouse, residues 1–30;
human, 1–23) and transmembrane
segments (TM; mouse, 200–333) are
indicated. B, Real-time RCR analysis
of Treml4 mRNA. Values are relative
to expression of the gene encoding
GAPDH. BMCs, bone marrow cells;
LNs, lymph nodes. C, HEK293 cells
were transiently transfected with the
indicated combination of Treml4-
FLAG, myc-FcR, myc-DAP10, and
myc-DAP12 (above lane). After 36 h,
cell lysates were immunoprecipitated
(IP) with anti-FLAG Ab, followed by
blotting (IB) with anti-myc Ab. WCL,
whole-cell lysate; n.s., nonspecific
bands. D, Thymocytes were exposed
to -irradiation to induce apoptosis,
and then stained with the indicated
chimeric fusion proteins. E, Thymo-
cytes were incubated at 56°C for 30
min and then stained with fusion pro-
teins and analyzed by FACS. Repre-
sentative data from at least two inde-
pendent experiments are shown.
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the CD8 subset that takes up dying cells (Fig. 1B). We selected
genes showing greater than 4-fold mRNA abundance in CD8 cells
for further investigation, e.g., CD36 and CD207, which were previ-
ously reported to be more abundantly expressed in CD8 DCs (3,
27, 28, 32). We confirmed the gene expression results either by FACS
analysis (CD36, CD103, and CD207; data not shown) or semiquan-
titative RT-PCR (C530028O21Rik, Fndc5, Cadm1, Mpzl2, and
Treml4; Fig. 1C). Thus, several transmembrane proteins were avail-
able as potential receptors on CD8 DCs for dying cells.
Binding of Fc fusion proteins to apoptotic or necrotic cells
To determine whether the identified CD8 DC proteins could
recognize apoptotic or necrotic cells, we generated soluble chi-
meric fusion forms of C530028O21Rik, Fndc5, Cadm1, Mpzl2,
and Treml4 proteins. These fusion proteins consisted of their ex-
tracellular domain fused to the human IgG1 Fc domain and were
produced mainly as dimers (data not shown). Apoptosis of spleno-
cytes was induced by -ray irradiation, and then these dying cells
were incubated with the individual chimeric proteins. As shown in
Fig. 2A, we could not detect any binding of fusion proteins to living
(PI annexin V) or early apoptotic (PI annexin V) cells. Inter-
estingly, Treml4 bound to late apoptotic (PI annexin V) spleno-
cytes. Also, Treml4 bound to various other sources of dying cells,
including thymocytes and the 293, EL4, and Chinese hamster ovary
tumor cell lines (Fig. 2B and data not shown). Because late apoptotic
cells, also called secondary necrotic cells, show similar membrane
integrity to necrotic cells, we next investigated whether these fusion
proteins bound to necrotic cells. Thymocytes were incubated at 56°C
for 30 min or 100°C for 10 min, and then stained with these fusion
proteins. Only Treml4, but not the other fusion proteins, bound to
necrotic cells that were positive for PI staining (Fig. 2C and data not
shown). Thus, a chimeric Treml4 fusion protein binds to PI-positive,
late apoptotic, and necrotic cells, but not living or early apoptotic
cells.
Treml4 associates with DAP12
Mouse Treml4 showed similar structural features to other members of
the Trem family (reviewed in Ref. 33), with a single V-type Ig-like
motif in the extracellular portion and a short cytoplasmic tail (Fig.
3A). Treml4 mRNA was predominantly expressed in spleen (Fig. 3B).
Trem1, 2, 3, and PDC-Trem are known to associate with and trans-
duce signals through an adaptor molecule DAP12 (34–37). This as-
sociation is mediated by a cationic lysine residue in the transmem-
brane domain, which was also found in the transmembrane region of
Treml4. To determine whether Treml4 associated with DAP12 or
other adaptor molecules such as DAP10 and FcR, HEK293A cells
were transiently transfected with an expression vector for FLAG-
tagged Treml4 together with expression vectors for myc-tagged
DAP12, DAP10, or FcR, and then their association was evaluated by
coimmunoprecipitation assay. As shown in Fig. 3C, we found that
Treml4 associated with DAP12, but not DAP10 nor FcR.
Although it is well known that Trem members can modulate
cellular responses to bacterial products (reviewed in Ref. 33), the
identity of natural ligands for them is largely unknown. It has been
reported that Trem2 recognizes anionic ligands expressed on bac-
teria (38), and more recently Takahashi et al. (39) reported that
Trem2 is involved in the clearance of apoptotic neurons by mi-
croglia. Therefore, we purified soluble forms (Fc fusion proteins)
of Trem1, 2, and 3, to investigate whether they could bind to ap-
optotic or necrotic cells. We found that Trem2, like Treml4, bound
to late apoptotic and necrotic cells, whereas Trem1 and Trem3 did
not exhibit detectable binding. Thus, Trem2- and Treml4-Fc fusion
proteins can bind to dead cells (Fig. 3, D and E).
Treml4 is expressed on a subset of DCs: FACS analyses
To further pursue the expression and biology of Treml4, we gen-
erated an anti-Treml4 mAb (Fig. 4A). We first investigated the
types of leukocytes that express Treml4 by FACS analysis. CD3
T cells or B220 B cells in spleen or lymph nodes did not express
Treml4 (Fig. 4B). For splenic DCs, CD11c cells were enriched
with anti-CD11c beads. Treml4 was more abundantly expressed on
CD8 DCs than CD8 DCs, which was consistent with results
from the microarray analyses and RT-PCR of splenic DCs (Fig.
4B). Another DC subset, plasmacytoid DCs that were B220
CD11c cells, showed at best low expression of Treml4 (Fig. 4B).
A similar expression pattern was observed with DCs from lymph
nodes (Fig. 4B). Thus, Treml4 is expressed on subsets of DCs,
especially on CD8 DCs, but not on lymphocytes.









100 101 10 2 103 104100 101 10 2 103 104
B220+ CD11c+
FIGURE 4. Distribution of Treml4 by FACS. A, Parental Chinese ham-
ster ovary cells or Treml4 stable transfectants were stained with anti-
Treml4 mAb. B, Splenocytes or lymph node cells were prepared with col-
lagenase digestion, and the cells were stained with control Ab (open
histogram) and anti-Treml4 Ab (gray histogram). The expression of
Treml4 was monitored by FACS on B220 B and CD3 T cells, CD8
and CD8 DCs (CD8CD11c and CD8CD11c, respectively), and
B220 plasmacytoid DCs (B220 CD11c).
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Treml4 is abundant on two groups of macrophages in tissue
sections of spleen
To investigate in more detail the distribution of Treml4, we stained
sections from spleen and lymph node with mAbs to Treml4 and
various macrophage markers. It is known that there are several
distinct types and locations of macrophages in spleen. Red pulp
macrophages express F4/80, CD68, and the macrophage mannose
receptor/CD206, and marginal zone macrophages are positive for
SIGN-R1/CD209b, whereas marginal metallophilic macrophages
express sialoadhesin/CD169 (reviewed in Ref. 40). Double stain-
ing for Treml4 mAb and Abs to either F4/80, SIGN-R1, or CD169
showed that Treml4 was expressed on F4/80 red pulp and
CD169 marginal metallophilic macrophages, but only very
weakly on SIGN-R1 marginal zone macrophages (Fig. 5). In
lymph node, however, we observed little, if any, staining of
macrophages for Treml4, indicating again that Treml4 is re-
stricted to selected populations of macrophages (data not
shown). These data indicate that Treml4 is primarily expressed
in spleen, consistent with the mRNA analyses (Fig. 3B), and in
spleen, Treml4 is predominantly expressed on macrophages,
but also some DCs.
Treml4 is expressed primarily in spleen: Western blotting
We further investigated the tissue distribution of Treml4 by West-
ern blotting. We developed a protocol (see Materials and Methods)
to homogenize various tissues for quantitative blotting studies. En-
dogenous Treml4 protein was readily detected in a spleen lysate
(Fig. 6A). However, the expression of Treml4 in lymph nodes was
less than that in spleen, because larger samples and longer expo-
sure times for development were required to obtain even a weak
Western blotting signal, whereas other macrophage Ags like CD68
and F4/80 were readily detected in lymph node (Fig. 6B). Among
several tissues, Treml4 protein was clearly detected only in spleen,
even though other macrophage markers were observed in all tissues
investigated, suggesting that Treml4 protein, as consistent with RT-
PCR analysis, is predominantly expressed in spleen (Fig. 6C). More-
over, although CD68 expression was not different between two strains
FIGURE 5. Views of the border of
red pulp (top) and white pulp (bottom)
of BALB/c mouse spleen. The B cell
follicle of the white pulp was marked
in blue by the anti-B220 mAb,
whereas the macrophages of the red
pulp and marginal zones were stained
in green for the indicated molecules.
The signal for Treml4 was stained in
red. Between the B cell follicle and
red pulp are concentric layers of two
types of macrophages: the marginal
metallophilic macrophages (white
vertical arrows), stained in green for
CD169 (A), and the SIGNR1 mar-
ginal zone macrophages (B and C for
higher magnification; E), which have
weak staining for Treml4. D, F4/80
Ag (green) is found on red pulp mac-
rophages, but not marginal metallo-
philic (white vertical arrow) and mar-
ginal zone macrophages (E). E, CD68
is abundant on red pulp macrophages
(green), but not on Treml4 (red)
marginal metallophilic macrophages
(white vertical arrows) or marginal
zone macrophages (E). F, As in E,
but MMR (green) is abundant on red
pulp macrophages, and not in mar-
ginal metallophilic (white arrows) or
marginal zone macrophages (E).
Scale  100 m, but C, where
scale  50 m. MMR, macrophage
mannose receptor.
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of mice, BALB/c and C57BL/6, Treml4 was more abundantly ex-
pressed in the spleen from BALB/c than C57BL/6 mice (Fig. 6D).
Thus, Treml4 is a distinctive marker in that it is peculiarly abundant
in spleen rather than other organs.
Treml4 expression is not altered after DC maturation
Bacterial products are reported to up-regulate expression of
TREM1 on human monocytes and neutrophils (34, 41), whereas
maturation stimuli down-regulate expression of human TREM2 on
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FIGURE 6. Tissue distribution of Treml4 by Western blotting. A, Representative data of the immunoblot signals for Treml4 and CD68 in BALB/c spleen
lysates from two mice (1 and 2). B, Expression of Treml4, F4/80, and CD68 was assayed in lymph nodes of BALB/c (B) or C57BL/6 (C) mice using
different amounts of protein (10 or 20 g) and different film exposure times (1, 3, or 10 min) to illustrate that signals were acquired under limiting conditions
for quantification. C, The expression of the indicated molecules was monitored by Western blotting. The indicated organs from BALB/c (B) or C57BL/6
(C) mice were lysed, and 10 g of protein (except for CD68 and F4/80 markers in peritoneal lavage; 2 or 1 g of protein was loaded, respectively) was
separated by SDS-PAGE. LNs, lymph nodes; BM, bone marrow; P. lavage, peritoneal lavage. D, Treml4 and CD68 were assayed by Western blot (upper
panel) and densitometry (lower panel) from three BALB/c (B; 1, 2, and 3) and three C57BL/6 (C; 1, 2, and 3) mice. Asterisk represents statistical difference
between both mice strains: , p  0.01.
FIGURE 7. Regulation of Treml4 expression on
DCs. MACS-enriched CD11c splenic DCs were
left unstimulated (medium) or stimulated with
poly(I:C) (10 g/ml), LPS (1 g/ml), or CpG DNA
(1 M). Twenty-four hours later, the expression of
Treml4 and CD40 was monitored by FACS. CD40
was used as a marker for DC activation by the TLR
ligands.
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immature DCs or mouse Trem2 on bone marrow-derived macro-
phages (42). Recently, a new Trem family member, termed PDC-
Trem, was found to be expressed on activated plasmacytoid DCs, but
not immature plasmacytoid DCs (37). Thus, the expression of Trem
family members can be differentially regulated. We therefore inves-
tigated Treml4 expression after DC activation. MACS-enriched
splenic CD11c DCs were stimulated with TLR ligands such as
poly(I:C) (TLR3), LPS (TLR4), or CpG DNA (TLR9) to activate
DCs, and the expression of Treml4 on DCs was monitored 24 h after
stimulation. The expression of Treml4 was clearly detected on freshly
isolated DCs. Although the relative frequency of CD8 DCs was
slightly reduced when the cells were cultured without any stimulus
(medium in Fig. 7), the expression of Treml4 on CD8 DCs was
retained. Treml4 on CD8 DCs was neither down- nor up-regulated,
even though DCs were activated by some TLR ligands, as indicated
by up-regulation of CD40 (Fig. 7). Thus, Treml4 expression was reg-
ulated distinctly from other Trem family members.
Discussion
We have identified a new member of the Trem family in mice and
found that it has a distinctive tissue distribution being primarily ex-
pressed on subsets of splenic macrophages (red pulp and marginal
metallophilic macrophages) and DCs (CD8 DCs). We also found
that the soluble form of Treml4 has binding affinity to necrotic cells.
DNA microarray analysis revealed that many genes were dif-
ferentially expressed between splenic CD8 and CD8 DCs,
where the former DCs selectively take up dying cells in vivo (3).
Consistent with previous reports, our microarray data indicated
that CD36, CD205 (DEC-205), CD207 (Langerin), and CD103
(E integrin) mRNA were each more abundantly expressed in
CD8 DCs. However, it had been reported that CD36- or DEC205-
deficient DCs could take up dying cells in vivo (3, 27, 28). Because
CD207 is weakly expressed on the surface of splenic DCs from
C57BL/6 mice (43), CD207 was not likely to be required for dying
cell uptake. Thus, none of these molecules expressed by CD8 DCs
seemed essential for their uptake of dying cells.
We further considered the C530028O21Rik, Fndc5, Cadm1,
Mpzl2, and Treml4 genes that were more abundantly expressed in
CD8 than CD8 DCs. Functional analyses of Cadm1 and
Mpzl2 knockout mice had not assessed uptake of dying cells (44–
47). When we prepared Fc fusion proteins of each of these five
genes, to see whether they could bind to dying cells, only Treml4
showed binding to necrotic PI annexin V cells, but not early
apoptotic cells in our study.
The predicted amino acid sequence of Treml4 showed character-
istic features of the Trem family, including the presence of a V-type
Ig-like motif in the extracellular portion and a short cytoplasmic tail
(reviewed in Ref. 33). Many Trem members, including Trem1, 2, 3,
and PDC-Trem, have a cationic lysine residue in their transmembrane
domain, which is essential for association with ITAM-bearing adaptor
molecule, DAP12. This lysine residue was also observed in the trans-
membrane domain of Treml4, and consistent with this, we observed
a Treml4/DAP12 association by immunoprecipitation assay.
To begin to study the biological features of Treml4, we found a
unique expression pattern. Real-time PCR and Western blotting
analysis indicated that Treml4 was predominantly expressed in the
spleen, and its expression was more abundant in BALB/c than
C57BL/6 spleen. Immunofluorescent staining of tissue sections and
FACS analysis of cell suspensions from spleen revealed that Treml4
was expressed on DCs as well as spleen resident macrophages, espe-
cially in red pulp and marginal metallophilic macrophages. Our quan-
titative Western blotting data indicated that the expression of Treml4
was primarily confined to macrophages in spleen, which is an unusual
feature relative to many other known macrophage products that we
studied, such as F4/80, CD68, CD169, and CD206.
Based on genomic sequencing data, the human Treml4 sequence
seems to be truncated around the predicted transmembrane domain
of its mouse counterpart (Fig. 3A, and reviewed in Ref. 33), sug-
gesting that human Treml4 may be produced only as soluble form
and/or is not functional. Mouse Trem2 is reported to be involved
in the clearance of apoptotic neurons by microglia (39). Human
Trem2 is expressed on macrophages and monocyte-derived DCs,
but mouse Trem2 is not expressed on splenic DCs (data not
shown). In our experiments, Trem2-Fc fusion protein could bind to
annexinV PI late apoptotic or necrotic cells just like Treml4-Fc.
At present, the ligand for Treml4 is not yet identified, and we do
not know whether Trem2- and Treml4-Fc fusion proteins bind to
the same molecules. A report suggests that ligands for Trem2 are
found on the surface of microbes and they are anionic molecules
(38). However, Treml4-Fc fusion protein did not bind to Esche-
richia coli or Staphylococcus aureus (supplemental figure).4 How-
ever, Trem2- and Treml4-Fc fusion protein bound to necrotic cells
that were incubated at 100°C, indicating that the ligands for Trem2
and/or Treml4 in necrotic cells are thermostable substances. There-
fore, we cannot rule out a possibility that Trem2 and Treml4 may
compensate functions for each other in mice.
It has been reported that signals from Trem members affect the
activation status of DCs and macrophages (33). Although both
Trem1 and Trem2 associate with DAP12, they can have contrast-
ing effects on immune cells. For example, whereas activation of
Trem1 showed a synergistic effect with TLR ligands (41), Trem2-
deficient macrophages show enhanced cytokine production in re-
sponse to TLR ligands (42). Furthermore, DAP12-deficient cells
showed enhanced or reduced cytokine production in response to
TLR ligands depending on the cell type or experimental conditions
(48, 49). It remains unclear whether activation of Treml4 can affect
cellular activation of DCs and, reciprocally, whether TLR ligands
intersect with Treml4 function on these cells.
Further studies are required to clarify whether Treml4 is in-
volved in the uptake of dying or necrotic cells and mediates im-
mune recognition in vivo. It has been reported that some C-type
lectins, including Lox-1, mannose-binding lectin, and Mincle, can
recognize dead cells or molecules leaked from them (50–52).
Trem2, which showed affinity to dead cells in our experiments
(Fig. 3E), is expressed on DCs and macrophages such as GM-
CSF-induced bone marrow-derived DCs and bone marrow-derived
or thioglycolate-elicited peritoneal macrophages in mice (42, 53).
Therefore, it is difficult to discriminate a role of Treml4 engage-
ment from the activation of other C-type lectins by dead cells in
wild-type DCs and macrophages. Treml4-deficient mice and cells
will help to clarify these points.
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